The JPJDF has Synergistic Effect with Fluoropyrimidine in the Maintenance Therapy for Metastatic Colorectal Cancer

Author(s): Xiaoling Fu*, Yanbo Zhang, Lisheng Chang, Dengcheng Hui, Ru Jia, Ningning Liu, Huayue Zhang, Gang Han, Zhifen Han, Yuan Li, Hui Liu, Huirong Zhu, Qi Li*

Journal Name: Recent Patents on Anti-Cancer Drug Discovery

Volume 15 , Issue 3 , 2020


Become EABM
Become Reviewer
Call for Editor

Abstract:

Background: Maintenance chemotherapeutic regimen with low toxicity is needed for metastatic colorectal cancer. A recent patent has been issued on the spleen-strengthening and detoxification prescription (JPJDF), a traditional Chinese herbal medicinal formula with anti-angiogenesis effect. The clinical effect of JPJDF on the maintenance treatment of advanced colorectal cancer has not been evaluated.

Objective: This study aims to evaluate the effectiveness and safety of JPJDF in combination with fluoropyrimidine compared to fluoropyrimidine alone as maintenance therapy for metastatic colorectal cancer.

Methods: We applied a prospective, randomized, double-blinded, single center clinical study design. A total of 137 patients with advanced colorectal cancer were recruited. Patients received either Fluoropyrimidine (Flu-treated group, n = 68), or Fluoropyrimidine plus JPJDF (Flu-F-treated group, n = 69) as maintenance treatment after 6-cycle of FOLFOX4 or FOLFORI induction treatment. The primary endpoints were Progression-Free Survival (PFS) and Overall Survival (OS). The secondary endpoints were safety, Performance Status (PS) score and other symptoms.

Results: The endpoint of disease progression was observed in 91.7% of patients. The PFS was 5.0 months and 3.0 months in the Flu-F-treated and Flu-treated groups, respectively. The OS was 15.0 months and 9.0 months in the Flu-F-treated and Flu-treated groups, respectively. Some common symptoms, such as hypodynamia, anepithymia, dizziness and tinnitus and shortness of breath, were improved in the Flu-F-treated group. There was no significant difference in the common adverse reactions between the two groups.

Conclusion: JPJDF and fluoropyrimidine have synergistic effect in the maintenance treatment of mCRC.

Keywords: Anti-angiogenesis, fluoropyrimidine, maintenance treatment, metastatic colorectal cancer, Progression-Free Survival (PFS), Overall Survival (OS).

Chin J Cancer Res Chen W. 29 1 2017 10.21147/j.issn.1000-9604.2017.01.01 Chen W.; Zheng R.; Zhang S.; Cancer incidence and mortality in China in 2013: An analysis based on urbanization level. Chin J Cancer Res 2017,29(1),1-10 Public Health Sharma T. 182 70 2020 10.1016/j.puhe.2020.01.021 Sharma T.; Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults. Public Health 2020,182,70-76 Chin J Cancer Zheng R. 36 66 2017 10.1186/s40880-017-0234-3 Zheng R.; Zeng H.; Zhang S.; Chen W.; Estimates of cancer incidence and mortality in China, 2013. Chin J Cancer 2017,36(1),66 World J Gastroenterol Kim S.E. 21 5167 2015 10.3748/wjg.v21.i17.5167 Kim S.E.; Paik H.Y.; Yoon H.; Lee J.E.; Kim N.; Sung M.K.; Sex- and gender-specific disparities in colorectal cancer risk. World J Gastroenterol 2015,21(17),5167-5175 J Surg Oncol Tsai H.L. 100 736 2009 10.1002/jso.21404 Tsai H.L.; Chu K.S.; Huang Y.H.; Predictive factors of early relapse in UICC stage I-III colorectal cancer patients after curative resection. J Surg Oncol 2009,100(8),736-743 J Clin Oncol Chibaudel B. 27 5727 2009 10.1200/JCO.2009.23.4344 Chibaudel B.; Maindrault-Goebel F.; Lledo G.; Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 2009,27(34),5727-5733 ACS J Siegel R. 63 11 2013 Siegel R.; Naishadham D.; Jemal A.; Cancer statistics 2013 CA: A cancer journal for clinicians. ACS J 2013,63(1),11-30 China Oncology Song S-P. 16 775 2006 Song S-P.; Liu B.; Advanced in medical treatment of metastatic colorectal cancer. China Oncology 2006,16(10),775-780 ESMO Open You X.H. 5 e000605 2020 10.1136/esmoopen-2019-000605 You X.H.; Jiang Y.H.; Fang Z.; Sun F.; Li Y.; Wang W.; Chemotherapy plus bevacizumab as an optimal first-line therapeutic treatment for patients with right-sided metastatic colon cancer: a meta-analysis of first-line clinical trials. ESMO Open 2020,5(2),e000605 Br J Cancer Codony-Servat J. 117 1777 2017 10.1038/bjc.2017.279 Codony-Servat J.; Cuatrecasas M.; Asensio E.; Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer. Br J Cancer 2017,117(12),1777-1786 Cancer Treat Rev Esin E. 42 82 2016 10.1016/j.ctrv.2015.10.012 Esin E.; Yalcin S.; Maintenance strategy in metastatic colorectal cancer: A systematic review. Cancer Treat Rev 2016,42,82-90 Nat Rev Gastroenterol Hepatol Keum N. 16 713 2019 10.1038/s41575-019-0189-8 Keum N.; Giovannucci E.; Global burden of colorectal cancer: Emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol 2019,16(12),713-732 Ferrara N 2018 Ferrara N; Nina K; Robert MD; VEGF-specific antagonists for adjuvant therapy and neoadjuvant therapy, and treatment of early stage tumors. JP2018052939, 2018 Rajasekhar K 2011 Rajasekhar K; Nariyam SM; Murki V; Preparation of capecitabine. US20110224422, 2011 Zhao Z 2013 Zhao Z; Hao G; Liu A; Method for preparing tegafur, gimeracil and oteracil potassium capsules. CN103211820, 2013 Ge S 2016 Ge S; Lin F; Huang J; Raltitrexed solvate and preparation method thereof. CN201611244886, 2016 Trials Shi M. 21 249 2020 10.1186/s13063-020-4194-6 Shi M.; Ma T.; Xi W.; A study of capecitabine metronomic chemotherapy is non-inferior to conventional chemotherapy as maintenance strategy in responders after induction therapy in metastatic colorectal cancer. Trials 2020,21(1),249 European J Cancer (Oxford, England: 1990) Gonzalez-Baron M 31a 2215 1995 Gonzalez-Baron M; Feliu J; de la Gandara I; Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study. European J Cancer (Oxford, England: 1990) 1995,31a(13-14),2215-2219 Oncologist Chen Y. 24 591 2019 10.1634/theoncologist.2018-0901 Chen Y.; Wu J.; Cheng K.; S-1 plus raltitrexed for refractory metastatic colorectal cancer: A Phase II trial. Oncologist 2019,24(5),591-e165 Zhongguo Yiyuan Yongyao Pingjia Yu Fenxi Lei Z. 774 2014 Lei Z.; Qin L.; Maintenance therapy in patients with advanced colorectal cancer: Selection of optimal regimen. Zhongguo Yiyuan Yongyao Pingjia Yu Fenxi 2014(9),774-777 eCAM Zhang S 2018 6180810 2018 10.1155/2018/6180810 Zhang S; Shi L; Mao D; Use of Jianpi Jiedu herbs in patients with advanced colorectal cancer: a systematic review and meta-analysis. eCAM 2018,2018,6180810 Complement Ther Med Chien T.J. 29 204 2016 10.1016/j.ctim.2016.10.001 Chien T.J.; Liu C.Y.; Lu R.H.; Kuo C.W.; Lin Y.C.; Hsu C.H.; Therapeutic efficacy of traditional Chinese medicine, “Kuan-Sin-Yin”, in patients undergoing chemotherapy for advanced colon cancer - A controlled trial. Complement Ther Med 2016,29,204-212 Tech Coloproctol Tan K.Y. 12 1 2008 10.1007/s10151-008-0392-z] Tan K.Y.; Liu C.B.; Chen A.H.; Ding Y.J.; Jin H.Y.; Seow-Choen F.; The role of traditional Chinese medicine in colorectal cancer treatment. Tech Coloproctol 2008,12(1),1-6 Biosci Trends Qi F. 9 16 2015 10.5582/bst.2015.01019 Qi F.; Zhao L.; Zhou A.; The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer. Biosci Trends 2015,9(1),16-34 Biomed Pharmacother Wang Y. 121 109570 2020 10.1016/j.biopha.2019.109570 Wang Y.; Zhang Q.; Chen Y.; Antitumor effects of immunity-enhancing traditional Chinese medicine. Biomed Pharmacother 2020,121,109570 J Nanjing Univ TCM Li-rong L.I.U. 30 19 2014 Li-rong L.I.U.; Yan-juan Z.H.U.; Meta-analysis on efficacy and life quality of advanced colorectal cancer with Chinese medicine combined with chemotherapy. J Nanjing Univ TCM 2014,30(1),19-21 J Clin Pharm Ther Ge L. 41 383 2016 10.1111/jcpt.12410 Ge L.; Wang Y.F.; Tian J.H.; Network meta-analysis of Chinese herb injections combined with FOLFOX chemotherapy in the treatment of advanced colorectal cancer. J Clin Pharm Ther 2016,41(4),383-391 Cochrane Database Syst Rev Guo Z. CD004653 2012 Guo Z.; Jia X.; Liu J.P.; Liao J.; Yang Y.; Herbal medicines for advanced colorectal cancer. Cochrane Database Syst Rev 2012(5),CD004653 Integr Cancer Ther Chien T.J. 15 113 2016 10.1177/1534735415617282 Chien T.J.; Liu C.Y.; Ko P.H.; Hsu C.H.; A Chinese decoction, Kuan-sin-yin, improves autonomic function and cancer-related symptoms of metastatic colon cancer. Integr Cancer Ther 2016,15(1),113-123 Sci Rep Zhu H. 8 7238 2018 10.1038/s41598-018-25500-x Zhu H.; Hao J.; Niu Y.; Liu D.; Chen D.; Wu X.; Molecular targets of Chinese herbs: A clinical study of metastatic colorectal cancer based on network pharmacology. Sci Rep 2018,8(1),7238 Chin J Integr Med Zhang T. 24 573 2018 10.1007/s11655-018-2980-0 Zhang T.; He W.T.; Zi M.J.; Song G.; Yi D.H.; Yang Y.F.; Cohort study on prognosis of patients with metastatic colorectal cancer treated with integrated Chinese and western medicine. Chin J Integr Med 2018,24(8),573-578 Li Q. 2016 Li Q.; A compound preparation of traditional Chinese medicine for colorectal cancer and its preparation. CN201610118611, 2016 Jilin J Chin Med Liu Guiwei. 006 584 2015 Liu Guiwei.; Ma Xiaoqun.; Ren Weidan.; Treatment of advanced colorectal cancer with compound Chinese medicine combined with capecitabine. Jilin J Chin Med 2015,006,584-586 Chin J Integr Med Sui H. 20 610 2014 10.1007/s11655-013-1452-4 Sui H.; Zhu H.R.; Wu J.; Effects of Jianpi Jiedu Recipe on reversion of P-glycoprotein-mediated multidrug resistance through COX-2 pathway in colorectal cancer. Chin J Integr Med 2014,20(8),610-617 Shanghai J Traditional Chinese Med Jian S. S1 181 2017 Jian S.; Yan W.; Qing J.; Hua S.; Jue Z.; Qi L.; Effects of Jianpi Jiedu recipe on expressions of DNA damage repair related genes in colorectal cancer. Shanghai J Traditional Chinese Med 2017,S1(51),181-184 Basic Clin Pharmacol Toxicol Sarac S.B. 124 237 2019 10.1111/bcpt.13192 Sarac S.B.; Ainsworth M.A.; Hovgaard D.; Bjerrum O.W.; Progression-Free Survival (PFS) in oncology: Caveat emptor! Basic Clin Pharmacol Toxicol 2019,124(3),237-238 N Engl J Med Chi K.N. 381 13 2019 10.1056/NEJMoa1903307 Chi K.N.; Agarwal N.; Bjartell A.; Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med TITAN Investigators2019,381(1),13-24 N Engl J Med Zhang Y. 381 1124 2019 10.1056/NEJMoa1905287 Zhang Y.; Chen L.; Hu G.Q.; gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med 2019,381(12),1124-1135 Jiang Q. 2007 Jiang Q.; Clinical Epidemiology. ( 1st [39] ed.), Beijing: Higher Education Press 2007 JAMA Oncol Sherman S.K. 5 236 2019 10.1001/jamaoncol.2018.5070 Sherman S.K.; Lange J.J.; Dahdaleh F.S.; Cost-effectiveness of maintenance capecitabine and bevacizumab for metastatic colorectal cancer. JAMA Oncol 2019,5(2),236-242 J Chin Integr Med Liu N.N. 8 968 2010 10.3736/jcim20101009 Liu N.N.; Zhou N.; Wang Y.; Chinese herbal medicine Jianpi Jiedu formula down-regulates the expression of vascular endothelial growth factor in human gastric cell line MKN45 induced by Helicobacter pylori by inhibiting cyclooxygenase-2. J Chin Integr Med 2010,8(10),968-973 Cancer Edeline J. 118 147 2012 10.1002/cncr.26255 Edeline J.; Boucher E.; Rolland Y.; Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 2012,118(1),147-156 World Chin J Digestology Wei B. 12 2701 2004 Wei B.; Chen Z.; Zhang W.; TCM syndrome score of gastrointestinal diseases. World Chin J Digestology 2004,12(11),2701-2703 Ann Transl Med Zhang Z. 6 121 2018 10.21037/atm.2018.02.12 Zhang Z.; Reinikainen J.; Adeleke K.A.; Pieterse M.E.; Groothuis-Oudshoorn C.G.M.; Time-varying covariates and coefficients in Cox regression models. Ann Transl Med 2018,6(7),121 Appl Neuropsych-Adul Abramson D.A. 6 1 2020 Abramson D.A.; Resch Z.J.; Ovsiew G.P.; Impaired or invalid? Limitations of assessing performance validity using the Boston naming test. Appl Neuropsych-Adul 2020,6(9),1-6 Surg Oncol Clin N Am Sugarbaker P.H. 21 689 2012 Sugarbaker P.H.; Early intervention for treatment and prevention of colorectal carcinomatosis: A plan for individualized care. Surg Oncol Clin N Am 2012,21(4),689-703 J Traditional Chinese Sun B. 33 479 2013 Sun B.; Meng J.; Xiang T.; Jianpi Jiedu fang improves survival of hepatocarcinoma mice by affecting phosphatase and tensin homolog, phosphoinositide 3-kinase, and focal adhesion kinase. J Traditional Chinese 2013,33(4),479-485 JAMA Oncol Wang Z.X. 6 937 2020 10.1001/jamaoncol.2020.0580 Wang Z.X.; Liang F.; Xu R.H.; The role of maintenance therapy in metastatic colorectal cancer. JAMA Oncol 2020,6(6),937 JAMA Oncol Sonbol M.B. 6 e194489 2020 10.1001/jamaoncol.2020.0583 Sonbol M.B.; Murad M.H.; Bekaii-Saab T.; The role of maintenance therapy in metastatic colorectal cancer-reply. JAMA Oncol 2020,6(3),e194489 ESMO Open Cardone C. 4 e000519 2019 10.1136/esmoopen-2019-000519 Cardone C.; Martinelli E.; Troiani T.; Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a Phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer. ESMO Open 2019,4(4),e000519 BMC Gastroenterol Su J. 19 17 2019 10.1186/s12876-018-0916-6 Su J.; Lai J.; Yang R.; Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: A retrospective analysis in Chinese postmenopausal women. BMC Gastroenterol 2019,19(1),17 Tang Z. 266 1993 Tang Z.; Modern Oncology.: Shanghai Medical University Press: Shanghai, China 1993,266-274 1998 China Anticancer Association New Criteria of the Diagnosis and Treatment of Common Malignant Tumors-Fascicle of Colorectal Cancer. : China Union Medical University Press: Beijing, China 1998 Ann Oncol Luo H.Y. 27 1074 2016 10.1093/annonc/mdw101 Luo H.Y.; Li Y.H.; Wang W.; Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: Randomized clinical trial of efficacy and safety. Ann Oncol 2016,27(6),1074-1081 EMBO Mol Med Deschoemaeker S. 7 1350 2015 10.15252/emmm.201505492 Deschoemaeker S.; Di Conza G.; Lilla S.; PHD1 regulates p53-mediated colorectal cancer chemoresistance. EMBO Mol Med 2015,7(10),1350-1365 Drug Metab Rev Marin J.J. 44 148 2012 10.3109/03602532.2011.638303 Marin J.J.; Sanchez de Medina F.; Castaño B.; Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer. Drug Metab Rev 2012,44(2),148-172 Biosci Rep Lin F. 2018 BSR20180641 2018 10.1042/BSR20180641 Lin F.; Li H.; Wang J.; Wang F.; Efficacy and toxicities of combination maintenance therapy in the treatment of advanced colorectal cancer: A meta-analysis of randomized controlled trials. Biosci Rep 2018,2018,BSR20180641 Lancet Haematol Barr P.M. 5 e102 2018 10.1016/S2352-3026(18)30001-2 Barr P.M.; Li H.; Burack W.R.; R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): A single-arm, Phase 2, multicentre study. Lancet Haematol 2018,5(3),e102-e108 Lancet Simkens L.H.J. 385 1843 2015 10.1016/S0140-6736(14)62004-3 Simkens L.H.J.; van Tinteren H.; May A.; Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): A phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet 2015,385(9980),1843-1852 Clin Colorectal Cancer Petrioli R. 17 e663 2018 10.1016/j.clcc.2018.07.002 Petrioli R.; Francini E.; Cherri S.; Capecitabine plus oxaliplatin and bevacizumab, followed by maintenance treatment with capecitabine and bevacizumab for patients aged > 75 years with metastatic colorectal cancer. Clin Colorectal Cancer 2018,17(4),e663-e669 Oncotarget Zhao L. 7 33418 2016 10.18632/oncotarget.8644 Zhao L.; Wang J.; Li H.; Che J.; Cao B.; Meta-analysis comparing maintenance strategies with continuous therapy and complete chemotherapy-free interval strategies in the treatment of metastatic colorectal cancer. Oncotarget 2016,7(22),33418-33428 Eur J Cancer Ruff P. 51 18 2015 10.1016/j.ejca.2014.10.019 Ruff P.; Ferry D.R.; Lakomỳ R.; Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy. Eur J Cancer 2015,51(1),18-26 Chin J Clin Oncol Rehabil Lai C-H. 2 194 2015 Lai C-H.; Zhang J-L.; Zheng W-B.; Clinical value of S-1 capsule in the maintenance treatment of advanced metastatic colorectal cancer. Chin J Clin Oncol Rehabil 2015,2,194-196 Medicine (Baltimore) Liu J. 98 e14326 2019 10.1097/MD.0000000000014326 Liu J.; Wang Y.; Jiang H.; Yu X.; Xu N.; Long-term survival of an elderly female with metastatic colon cancer after treated with capecitabine monotherapy: A case report. Medicine (Baltimore) 2019,98(5),e14326 Jiangsu Medical J Wei Wang. 41 2318 2015 Wei Wang.; Wu Changping.; Sun Wenhui.; Efficacy of tegafur and capecitabine in the maintenance treatment of advanced colorectal cancer. Jiangsu Medical J 2015,41(19),2318-2319 Ann Oncol Kwakman J.J.M. 28 1288 2017 10.1093/annonc/mdx122 Kwakman J.J.M.; Simkens L.H.J.; van Rooijen J.M.; Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group. Ann Oncol 2017,28(6),1288-1293 Integr Med Res Sui X. 8 21 2019 10.1016/j.imr.2018.11.001 Sui X.; Guo Y.; Ni W.; Jin H.; Lin H.; Xie T.; Molecular profiling analysis for colorectal cancer patients with Pi-Xu or Shi-Re syndrome. Integr Med Res 2019,8(1),21-25 J Trad Chin Med Li Y. 38 299 2018 Li Y.; Gu J.; Zhou H.; Traditional Chinese Medicine symptom patterns in patients with colorectal carcinoma. J Trad Chin Med 2018,38(2),299-308 J Exp Tradit Med Formulae Jiang G 19 323 2013 Jiang G; Zhang G; Dan RJCJETMF; Clinical curative effect observation of traditional Chinese and Western medicine combination for treatment of advanced colorectal cancer. J Exp Tradit Med Formulae 2013,19(12),323-5 BioMed Res Int Liu X. 2017 2613198 2017 10.1155/2017/2613198 Liu X.; Ji Q.; Deng W.; JianPi JieDu recipe inhibits epithelial-to-mesenchymal transition in colorectal cancer through TGF-β/Smad mediated Snail/E-cadherin expression. BioMed Res Int 2017,2017,2613198 Zhongguo Yi Xue Ke Xue Yuan Xue Bao Yu K-N. 38 686 2016 Yu K-N.; Ni Z-H.; Wang N-S.; A clinical multicenter randomized controlled study on Jianpi Qinghua decoction in treating stage 3 chronic kidney disease with a syndrome type of dampness-heat due to spleen deficiency. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2016,38(6),686-695 Jiangsu Traditional Chinese Medicine Yang Y. 51 40 2019 Yang Y.; Tang Y.; wanly Deng, Qi Li. Clinical study on the intervention effect of Jianpi Jiedu recipe on high risk population of colorectal cancer. Jiangsu Traditional Chinese Medicine 2019,51(1),40-42 CJTCMP Zhang Y. 30 2090 2015 Zhang Y.; Xuan L.; Qing J.; Zhou L.; Clinical research on treating metastatic colorectal cancer with Jianpi Jiedu Decoction and chemotherapy. CJTCMP 2015,30(6),2090-2093 Chin J Integr Med Yang Y.F. 14 251 2008 10.1007/s11655-008-0251-9 Yang Y.F.; Ge J.Z.; Wu Y.; Cohort study on the effect of a combined treatment of traditional Chinese medicine and Western medicine on the relapse and metastasis of 222 patients with stage II and III colorectal cancer after radical operation. Chin J Integr Med 2008,14(4),251-256 BMJ Open Gastroenterol Klepp P. 7 e000361 2020 10.1136/bmjgast-2019-000361 Klepp P.; Brackmann S.; Cvancarova M.; Risk of colorectal cancer in a population-based study 20 years after diagnosis of ulcerative colitis: Results from the IBSEN study. BMJ Open Gastroenterol 2020,7(1),e000361 Clin Colorectal Cancer Sunakawa Y. 16 e171 2017 10.1016/j.clcc.2016.09.010 Sunakawa Y.; Ichikawa W.; Tsuji A.; Prognostic impact of primary tumor location on clinical outcomes of metastatic colorectal cancer treated with cetuximab plus oxaliplatin-based chemotherapy: A subgroup analysis of the JACCRO CC-05/06 trials. Clin Colorectal Cancer 2017,16(3),e171-e180 Clinical study of Jianpijiedu-Decoction plus FOLFOX4 regimen in the treatment of advanced colorectal cancer Global Traditional Chinese Medicine Zhang Y. 2 2010 Zhang Y.; Xu J.H.; Sun J.; Clinical study of Jianpijiedu-Decoction plus FOLFOX4 regimen in the treatment of advanced colorectal cancer Global Traditional Chinese Medicine 2010,2 J Surg Oncol Mahar A.L. 116 969 2017 10.1002/jso.24774 Mahar A.L.; Compton C.; Halabi S.; Hess K.R.; Weiser M.R.; Groome P.A.; Personalizing prognosis in colorectal cancer: A systematic review of the quality and nature of clinical prognostic tools for survival outcomes. J Surg Oncol 2017,116(8),969-982 Eur J Cancer (Oxford, England: 1990) Brule SY 51 1405 2015 Brule SY; Jonker DJ; Karapetis CS; Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. Eur J Cancer (Oxford, England: 1990) 2015,51(11),1405-14 J Altern Complement Med Block K.I. 24 890 2018 10.1089/acm.2018.0125 Block K.I.; Block P.B.; Gyllenhaal C.; Integrative treatment for colorectal cancer: A comprehensive approach. J Altern Complement Med 2018,24(9-10),890-901


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 3
Year: 2020
Page: [257 - 269]
Pages: 13
DOI: 10.2174/1574892815666200717141205
Price: $65

Article Metrics

PDF: 53
HTML: 1